ES2578477T3 - ASC como marcador de la enfermedad pulmonar obstructiva crónica (EPOC) - Google Patents

ASC como marcador de la enfermedad pulmonar obstructiva crónica (EPOC) Download PDF

Info

Publication number
ES2578477T3
ES2578477T3 ES12707316.1T ES12707316T ES2578477T3 ES 2578477 T3 ES2578477 T3 ES 2578477T3 ES 12707316 T ES12707316 T ES 12707316T ES 2578477 T3 ES2578477 T3 ES 2578477T3
Authority
ES
Spain
Prior art keywords
copd
asc
pulmonary disease
chronic obstructive
obstructive pulmonary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12707316.1T
Other languages
English (en)
Inventor
Herbert Andres
Johann Karl
Julia Riedlinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Original Assignee
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Roche Diagnostics GmbH filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2578477T3 publication Critical patent/ES2578477T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Método in vitro para diferenciar la enfermedad pulmonar obstructiva crónica (EPOC) del asma en un sujeto humano, que comprende: a) determinar la concentración de proteína ASC en una muestra de suero, plasma o sangre completa, y b) comparar la concentración de proteína ASC determinada en la etapa (a) con una concentración de referencia de proteína ASC, en la que una concentración de proteína ASC superior a una concentración de referencia es indicativa de EPOC.
ES12707316.1T 2011-03-11 2012-03-07 ASC como marcador de la enfermedad pulmonar obstructiva crónica (EPOC) Active ES2578477T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11157917 2011-03-11
EP11157917 2011-03-11
PCT/EP2012/053847 WO2012123299A1 (en) 2011-03-11 2012-03-07 Asc as marker for chronic obstructive pulmonary disease (copd)

Publications (1)

Publication Number Publication Date
ES2578477T3 true ES2578477T3 (es) 2016-07-27

Family

ID=45808951

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12707316.1T Active ES2578477T3 (es) 2011-03-11 2012-03-07 ASC como marcador de la enfermedad pulmonar obstructiva crónica (EPOC)

Country Status (8)

Country Link
US (1) US9116156B2 (es)
EP (1) EP2684051B1 (es)
JP (1) JP5976695B2 (es)
CN (1) CN103403555B (es)
CA (1) CA2826820A1 (es)
ES (1) ES2578477T3 (es)
HK (1) HK1187103A1 (es)
WO (1) WO2012123299A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2583084T3 (es) * 2011-03-11 2016-09-19 F. Hoffmann-La Roche Ag NNMT como marcador para la enfermedad pulmonar obstructiva crónica (EPOC)
KR101568731B1 (ko) 2013-01-07 2015-11-13 재단법인 아산사회복지재단 만성폐쇄성폐질환 진단용 마커 조성물
US10087449B2 (en) 2014-04-07 2018-10-02 Shionogi & Co., Ltd. Pharmaceutical composition for treating chronic kidney disease
TWM527082U (zh) * 2016-04-11 2016-08-11 Probe Jet Tech 智慧型冰箱
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
EP3562506A4 (en) 2016-12-29 2021-01-06 University of Miami METHOD OF MODULATION OF INFLAMMATORY SOMACTIVITY AND INFLAMMATION OF THE LUNG
CN107267658B (zh) * 2017-08-21 2018-11-02 常州市第二人民医院 Copd诊断用分子标志物
US20210284723A1 (en) * 2018-07-03 2021-09-16 University Of Miami Compositions and methods for treating inflammasome related diseases or conditions
CN112285338B (zh) * 2020-10-20 2023-04-28 四川大学华西医院 一种copd诊断试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20030224438A1 (en) * 2002-05-24 2003-12-04 Millennium Pharmaceuticals, Inc. Novel molecules of the PYRIN/NBS/LRR protein family and uses thereof
JP2006526140A (ja) 2002-12-24 2006-11-16 バイオサイト インコーポレイテッド 鑑別診断のためのマーカーおよびその使用方法
CN101088012A (zh) * 2004-12-23 2007-12-12 霍夫曼-拉罗奇有限公司 Asc作为结肠直肠癌的标记的用途
WO2006105252A2 (en) * 2005-03-28 2006-10-05 The Regents Of The University Of Colorado Diagnosis of chronic pulmonary obstructive disease and monitoring of therapy using gene expression analysis of peripheral blood cells
CA2632327A1 (en) * 2005-12-22 2007-06-28 F. Hoffmann-La Roche Ag Use of a marker combination comprising osteopontin and carcinoembryonic antigen in the assessment of colorectal cancer
WO2007077042A1 (en) * 2006-01-06 2007-07-12 Topotarget Switzerland Sa New method for the treatment of gout or pseudogout
CA2706115A1 (en) 2007-12-10 2009-06-18 F. Hoffmann-La Roche Ag Seprase as a marker for cancer
WO2009074988A1 (en) * 2007-12-10 2009-06-18 Medical Research Fund Of Tel Aviv Sourasky Medical Center Methods of diagnosing cancer
EP2300000A1 (en) * 2008-07-03 2011-03-30 University of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
FI120949B (fi) 2008-07-10 2010-05-14 Waertsilae Finland Oy Menetelmä ja järjestely polttokennojärjestelmän esilämmityksen tehostamiseksi

Also Published As

Publication number Publication date
EP2684051A1 (en) 2014-01-15
EP2684051B1 (en) 2016-04-27
US20140004543A1 (en) 2014-01-02
CA2826820A1 (en) 2012-09-20
JP2014509741A (ja) 2014-04-21
HK1187103A1 (en) 2014-03-28
CN103403555A (zh) 2013-11-20
US9116156B2 (en) 2015-08-25
CN103403555B (zh) 2015-06-24
JP5976695B2 (ja) 2016-08-24
WO2012123299A1 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
ES2578477T3 (es) ASC como marcador de la enfermedad pulmonar obstructiva crónica (EPOC)
BR112013010015A2 (pt) aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos
EP2907792A4 (en) DIAMOND NANOPARTICLE AND PROCESS FOR PRODUCING THE SAME, AND FLUORESCENT MOLECULAR PROBE AND METHOD OF ANALYZING THE STRUCTURE OF A PROTEIN
EA201590027A1 (ru) Способы детекции заболеваний или состояний
BR112015020078A8 (pt) método para aumentar uma experiência de jogo e dispositivo de monitoramento de atividade física
WO2013107459A3 (en) Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples
MX2018004206A (es) Metodos para diagnosticar enfermedades infecciosas utilizando medios de adsorcion.
BR112014011818A2 (pt) método para realizar ensaios de quantificação
WO2015176066A3 (en) Lpa-associated protein and rna expression
CL2012002415A1 (es) Anticuerpo monoclonal aislado que se une al inhibidor de la via del factor tisular humano (tfpi); composicion farmacéutica que comprende dicho anticuerpo; procedimientos para tratar deficiencias o defectos genéticos o adquiridos en la coagulación; molecula de acido nucleico que codifica el anticuerpo; vector y célula huesped.
BR112016009460A8 (pt) método para detectar a presença de anticorpos neutralizantes, e, kit
FI20115670A0 (fi) Kardiovaskulaarinen in vitro-malli
WO2014140362A3 (en) Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc)
GB201201766D0 (en) Method
GB2523211A8 (en) MCT protein inhibitor-related prognostic and therapeutic methods
EP2882341A4 (en) KITS AND METHODS FOR DETERMINING THE PHYSIOLOGICAL RATE OR RATE AND / OR BEACH OR BEACHES OF HEMOGLOBIN AND / OR DISEASE CONDITION
RU2011135258A (ru) Способ прогнозирования частоты обострения хронической обструктивной болезни легких
BR112015017432A2 (pt) métodos para o tratamento de indicações cardiovasculares
BR112015013498A2 (pt) método para o diagnóstico de leucodistrofia metacromática
BR112014027413A2 (pt) biomarcadores para terapia com inibidor de iap
JP2015521041A5 (es)
MY170201A (en) A method for identifying a ganoderma-infected palm tree
WO2012119150A3 (en) Lung cancer-relevant human embryonic stem cell signature
BR112014018865A8 (pt) Biomarcador para as doenças inflamatórias pulmonares crônicas
UA63754U (ru) Способ определения тяжести заболевания гриппом